Rising Star Clinical Diagnostic Tool Category Eyenuk has been named a finalist in the Rising Star Clinical Diagnostic Tool category of the UCSF Digital Health Awards. Produced by the University …
Eyenuk named 2022 UCSF Digital Health Awards Finalist Read More »
Program selects Eyenuk’s EyeArt AI system to make vision-saving screening more accessible in remote Ontario communities LOS ANGELES and TORONTO, August 16, 2022 – Vision Loss Rehabilitation Canada (VLRC), Canada’s …
May 17, 2022 – Meritus Health, the largest provider of healthcare in western Maryland, recently adopted the EyeArt® artificial intelligence (AI) system for autonomous diabetic retinopathy testing in its primary …
Meritus Health Adopts the EyeArt® AI System for Autonomous Diabetic Eye Testing Read More »
March 28, 2022 – Eyenuk was recently featured in a Medical Tribune article highlighting the need for autonomous artificial intelligence (AI) systems for regular diabetic eye testing. In this article, …
Eyenuk was recently higlighted in a Reuters Legal feature discussing the historic decision by the United States Centers for Medicare and Medicaid Services to reimburse providers for the use of …
LOS ANGELES, Oct. 10, 2019 – Imagine if the very first signs of dementia, before any significant memory or other physiological changes are apparent, could be identified via a simple …
Landmark Study of Over 100,000 Diabetes Patient Visits Published in the Journal Diabetes Technology and Therapeutics Validates the Prowess of the EyeArt AI System for Diabetic Retinopathy Screening LOS ANGELES, …
July 30, 2019. Chicago, IL: The results of a prospective study, titled “Artificial Intelligence Screening for Diabetic Retinopathy: Analysis from a Pivotal Multi-center Prospective Clinical Trial,” were presented at the …
Strong EyeArt® Accuracy Results Presented by Professor Jennifer Lim at ASRS 2019 Read More »
LOS ANGELES, June 5, 2019 – Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today …
LOS ANGELES, CA, May 16, 2019 – Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced …
LOS ANGELES–(BUSINESS WIRE)–Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today that it will release results …
LOS ANGELES, Calif., April 28, 2019 – Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced …
APRIL 11 2019, LOS ANGELES–(BUSINESS WIRE)–Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today the …
Since our logo contains all letters in uppercase (“EYENUK”) people are often confused as to how to use it in a sentence, Eyenuk or EyeNuk? To further add to the …
Combining the high accuracy of AI disease detection with the accepted practice of human grading, the EyeScreen™ Service for diabetic retinopathy (DR) identifies cases of referable DR in any clinical …
EyeScreen™ Human+AI Diagnostic Service to be launched at ATA 2019 Read More »
Eyenuk’s logo was originally conceived back in early 2013 , to give the viewer the impression of staring at a “real” 3-dimensional eye, while giving it an orange hue to …
Eyenuk Inc., a global artificial intelligence (AI) medical technology company, is pleased to announce that it has successfully cleared an independent HIPAA audit. As a leader in real-world AI eye …
Eyenuk successfully clears HIPAA audit by A-Lign Read More »
LOS ANGELES, California, Oct. 2, 2018 – Eyenuk, Inc. announces its expansion into Germany with the adoption of EyeArt® artificial intelligence (AI) technology for the screening of diabetic retinopathy at …
A new study published in the international ‘Eye’ journal (Springer Nature) demonstrated very high sensitivity for detecting any diabetic retinopathy (95.8%) and sight-threatening diabetic retinopathy (99.1%) using EyeArt™ automated screening software with Remidio Fundus …
Eyenuk’s quality management system has been registered under the Medical Device Single Audit Program (“MDSAP”) as conforming to the requirements of ISO 13485:2003, after successfully completing an audit for the …
